Patent Awarded for Quadracentric SIJF Procedure | Orthopedics This Week
audio

Patent Awarded for Quadracentric SIJF Procedure

Courtesy of Captiva Spine, Inc.

Jupiter, Florida-based Captiva Spine, Inc. recently announced that it has been awarded a new patent for the site preparation approach used for its posterior sacroiliac (SI) joint fusion system, TransFasten®. The approach, named Quadracentric™, resembles a mortise and tenon or butterfly joint used in carpentry, resulting in the need for only a single implant.

The procedure involves drilling 4 small holes, one at each corner of a square, followed by a single large hole centered in the square resulting in a lobed hole with a wide area of decortication. The anchored cannula ensures the holes are drilled in precise locations to the predetermined depth.

The TransFasten implant is a specially machined structural allograft that fits perfectly in the space created. Once inserted the lobed design helps to resist torsional and sheer forces at the joint providing immediate stabilization. Bone graft is also inserted into the graft window of the implant before insertion, as well as packed into the remaining space in the hole above the implant.

The inventor of TransFasten, Robert Lins, M.D., is also a surgeon at the Center for Bone and Joint Surgery of the Palm Beaches in Florida. He claims that, “As Captiva Spine continues to introduce TransFasten, many will bring this procedure to their practice simply for the safety of the posterior approach coupled with this unique approach to SI joint fusion site preparation.”

He also shared his understanding of the SI joint’s role, and why it often causes pain, “Because the sacroiliac joints transfer forces from the upper body to the lower extremities, they are subject to trauma and chronic degenerative changes. I truly believe the TransFasten procedure will enable the medical community to better serve their patients suffering these degenerative changes in the future.”

Because the device is made of structural allograft, it is not subject to the 510(k) or PMA regulatory pathways.

  •  
  •  
  •  
  •  
  •  
  •  
  •  
Advertisement

Share Your Thoughts

Your email address will not be published.

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Advertisement